Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced it has signed a non-binding Letter of Intent to evaluate acquiring a Management Services Organization (MSO). If completed, the transaction could expand Tevogen's healthcare infrastructure and support its evolution into a revenue-generating enterprise with combined annual revenue of approximately $100 million, alongside its biotechnology and AI technology arms.

05/21/2026, 12:15 PM • Benzinga

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Tevogen Bio Holdings Inc. announced capital discipline measures including its lead investor Dr. Manmohan Patel's commitment to maintain shareholdings, a pledge to limit share utilization to 1% of authorized shares over the next 12 months or until cash-flow positive, and evaluation of acquisitions that could generate over $50 million in combined annual revenue. The company is also exploring ways to better reflect the value of its assets and continues to evaluate a potential special cash dividend.

03/13/2026, 2:45 PM • GlobeNewswire

Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced progress on TVGN 489, its investigational T-cell therapy for Long COVID, following the appointment of a new leadership team on March 9, 2026. The company expanded HLA target coverage to reach 65% of the U.S. population and is evaluating the acquisition of Sciometrix's Clinicus platform for real-world patient monitoring. Proof-of-concept data showed 100% of treated high-risk patients did not develop Long COVID.

03/11/2026, 3:15 PM • GlobeNewswire

Tevogen Bio Explores Buyout To Boost Generics Platform

Tevogen Bio Holdings (NASDAQ:TVGN) announced a non-binding Letter of Intent to explore acquiring Apozeal Pharmaceutical Inc. to strengthen its generics platform and enhance pharmaceutical affordability. The stock surged to $10.8 before falling, and is now trading at a 52-week low of $6.56, down 15.41% on the day. The company also approved a 50-for-1 reverse stock split and is considering other life sciences transactions.

03/06/2026, 12:42 PM • Benzinga

Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical

Tevogen Bio Holdings (NASDAQ: TVGN) announced a signed Letter of Intent to evaluate a potential acquisition of Apozeal Pharmaceutical, a company focused on cost-effective medicines. The acquisition would provide Tevogen with 11 FDA-approved generic drugs, multiple pending applications, and a development pipeline, supporting its Tevogen Generics initiative aimed at domestic pharmaceutical manufacturing and affordability. The transaction remains subject to due diligence and customary closing conditions.

03/05/2026, 2:50 PM • Benzinga

Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced a non-binding Letter of Intent to evaluate the potential acquisition of Apozeal Pharmaceutical, a generics-focused pharmaceutical company. The deal would provide Tevogen with 11 FDA-approved generic drugs, multiple pending ANDAs, and a development pipeline, supporting its Tevogen Generics initiative aimed at domestic pharmaceutical manufacturing and affordability. The transaction remains subject to due diligence and definitive documentation.

03/05/2026, 2:50 PM • GlobeNewswire

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

Tevogen Bio Holdings (NASDAQ: TVGN) announced it has signed a non-binding Letter of Intent to evaluate acquiring Sciometrix Inc., a healthcare technology company that develops the Clinicus digital care management platform. The potential transaction would result in Tevogen holding a majority voting interest in Sciometrix and aims to transform Tevogen into a revenue-generating healthcare enterprise by integrating digital care management capabilities with its Tevogen.AI initiative.

02/26/2026, 4:22 PM • Benzinga

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

Tevogen Bio Holdings (NASDAQ: TVGN) announced it has signed a non-binding Letter of Intent to evaluate acquiring Sciometrix Inc., a healthcare technology company that develops the Clinicus digital care management platform. The potential transaction would result in Tevogen holding a majority voting interest in Sciometrix and aims to integrate digital care management capabilities with Tevogen.AI to create a revenue-generating healthcare enterprise combining biotech with healthcare services.

02/26/2026, 9:20 AM • Benzinga

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

Tevogen Bio Holdings Inc. announced that its Board of Directors intends to evaluate a potential one-time special cash dividend to shareholders, contingent upon achieving specified financial milestones including revenue and earnings targets. The dividend would be subject to future financial performance, capital requirements, and solvency compliance, with no assurance of declaration or timing.

01/30/2026, 3:00 PM • GlobeNewswire

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue

Tevogen Bio Holdings Inc. announced modifications to its long-term stock incentive program to tie awards to defined company milestones including revenue targets. The company aims to launch at least four blockbuster products by 2030 and pursue revenue generation in 2026 through current programs, asset acquisitions, and joint ventures. Tevogen operates as a diversified healthcare company combining T cell therapy and AI-driven drug development platforms.

01/29/2026, 2:45 PM • GlobeNewswire

Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook

Tevogen Bio was recognized by NJBIZ for its innovative ExacTcell™ platform and AI technology, with projected near-term commercial potential of $1 billion in first-year revenue and a five-year forecast of $18-22 billion.

12/08/2025, 2:50 PM • GlobeNewswire

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

Tevogen Bio explains its accumulated deficit of $129 million, highlighting that the majority represents non-cash expenses and is offset by additional paid-in capital, with total cash loss under $42 million.

11/03/2025, 2:45 PM • GlobeNewswire

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

Tevogen Bio is developing an investigational precision T cell therapy (TVGN 489) for COVID-19 and Long COVID, with a favorable safety profile demonstrated in clinical trials and plans to collaborate with government and healthcare organizations.

10/15/2025, 3:50 PM • GlobeNewswire

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans

Tevogen expressed gratitude to HHS for addressing Long COVID, highlighting its investigational drug TVGN 489 as a potential treatment for the approximately 20 million Americans affected by the condition.

09/19/2025, 3:40 PM • GlobeNewswire

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

Tevogen's CEO, Dr. Ryan Saadi, donated 10,000 personal shares to the Warren Township Honorary Policemen's Benevolent Association (P.B.A.) Local 235, supporting local community and law enforcement initiatives.

08/18/2025, 5:50 PM • GlobeNewswire